US-based biotechnology company Pandion Therapeutics raised $58m in a series A round on Thursday from a consortium co-led by Roche Venture Fund, the investment unit of pharmaceutical firm Roche.
Polaris Partners and Versant Ventures co-led the round, which also featured SR One, the corporate venturing division of pharmaceutical firm GlaxoSmithKline, and BioInnovation Capital also participated.
Pandion is developing bispecific antibody therapeutics that are able to restore immune functionality and target specific tissue, avoiding the systemic immunosuppression required by current autoimmune…
